Hyderabad-based biopharmaceutical company Suven Life Sciences Limited has secured product patents in Russia and Australia for two of its New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases. These patents are valid until 2023.
"We are very pleased by the issuance of these patents in these countries to Suven for our drug candidates that are being developed for Central Nervous system(CNS) disorders which targets a $18 billion potential market opportunity globally," Venkat Jasti, Chief Executive of Suven, stated in a press release.
These granted patents are exclusive intellectual property of Suven and are achieved through the exclusive internal discovery research efforts. Products out of these inventories, which are in pre-clinical development may be licensed at the clinical Phase-I or II stage.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven which are being developed as therapeutic agents.
They are useful in the treatment of cognitive impairment associated with neuro-degenarative disorders like attention deficient hyperactivity, Alzheimer's, Parkinson, Schizophrenia and Huntington's.